PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval
Status:
Completed
Trial end date:
2024-02-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the PK effects of SHR4640 tablets on repaglinide and
midazolam, as well as the effects of SHR4640 tablets on the QT interval in healthy subjects.